Candida albicans, Staphyloccoccus and Infectious Challenge:
Rice PJ, Adams EL, Ozment-Skelton T, Gonzales A, Goldman MP, Lockhart BE, Barker LA, Breuel KF, Deponti WK, Kalbfleisch JH, Ensley HE, Brown GD, Gordon S, Williams DL.; “Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge.” East Tennessee State University. J Pharmacol Exp Ther. Jun 23, 2005.
Direct Quote: ”Oral glucan administration also increased survival in mice challenged with Staphylococcus aureus or Candida albicans …[and] increase[s] IL-12 expression and induce[s] protection against infectious challenge.”
Candida albicans:
Gantner BN, Simmons RM, Underhill DM. “Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments”; The Department of Immunology, University of Washington, Seattle, WA, Embo J; 23:24(6):1277.86, Mar 2005;
Direct Quote: “Dectin-1 is a receptor that binds beta-glucans and is important for macrophage phagocytosis of fungi. … the normal mechanisms of yeast budding and cell separation create permanent scars which expose sufficient beta-glucan to trigger antimicrobial responses through Dectin-1, including phagocytosis and activation of reactive oxygen production [anti-oxidant - free radical neutralization].”
Browder IW., et al., “Modification of Post-Operative C. albicas Sepis by Glucan Immunostimulation,” Int. J. Immunopharmac.; 6:19-26. Dept of Surg and Physiol, Tulane U Sch of Med, LA; 1984.
Direct Quote: “Protection against C. albicans was observed in the glucan-treated groups. ...These observations suggest that Biologic Response Modifiers such as glucan may be effectively employed in patients who are at risk for post-operative infections
ClinicalImmunity.com © 2008